Animal & Plant Derived Vaccines


Track 17: Animal & Plant Derived Vaccines

It has been about 30 years since the first plant engineering technology was established. Although the concept of plant-based pharmaceuticals or vaccines motivates us to develop practicable commercial products using plant engineering, there are some difficulties in reaching the final goal: to manufacture an approved product. At present, the only plant-made vaccine approved by the United States Department of Agriculture is a Newcastle disease vaccine for poultry that is produced in suspension-cultured tobacco cells. The progress toward commercialization of plant-based vaccines takes much effort and time, but several candidate vaccines for use in humans and animals are in clinical trials. This review discusses plant engineering technologies and regulations relevant to the development of plant-based vaccines and provides an overview of human and animal vaccines currently under clinical trials.


    Related Conference of Animal & Plant Derived Vaccines

    November 04-05, 2022

    34th Annual Congress on Vaccine and Clinical Trials

    Toronto, Canada
    November 17-18, 2022

    2nd Global Summit on Vaccines and Immunology

    Berlin, Germany
    February 20-21, 2023

    International Conference on Vaccine Research

    Madrid, Spain
    November 06-07, 2023

    5th World Congress on Vaccine and Immunology

    Tokyo, Japan

    Animal & Plant Derived Vaccines Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in